In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to treat acquired or inherited diseases, announces today the presentation of results obtained between ICA and two top 10 pharma at the 16th Annual Discovery on Target that will be held from 25 to 28 of September 2018 in Boston during the Antibody Discovery Programs session.
The presentation of ICA collaborative results at this industry’s preeminent event on novel drug targets with over 1,300 international participants, reflects on ICA expertise to efficiently immunize animals with Nanotaxi® technology.
During the meeting, speakers will have the opportunity to introduce the results on the use of the breakthrough ICANtibodies™ to immunize transgenic animals for the discovery of fully human antibodies with potential therapeutic use in human. ICANtibodies™ is a fully integrated antibodies discovery process without peptide and recombinant protein (from plasmid DNA antigen design and synthesis, Nanotaxi®/plasmid formulation and immunization in various species, to antibody quality controls). The figure below is the process of ICANtibodies™.
Nanotaxi®, the proprietary In-Cell-Art formulations, makes ICANtibodies™ unique compared to other genetic immunization-based antibodies discovery since Nanotaxi® dramatically increases expression of the gene-encoded antigen and hugely stimulates the innate immune system through a unique delivery mechanism.
The combination of these two properties allows the Nanotaxi® to generate powerful immune responses and antibodies of interest even against extremely difficult targets such as complex of integral membrane proteins and proteins with high homology. Discovered antibodies are of high quality with high specificity and high affinity (~pM).